July 21, 2017 1:36 PM ET

Capital Markets

Company Overview of Versant Venture Management, LLC

Company Overview

Versant Ventures is a venture capital firm specializing in incubation, seed, start-ups, and early stage investments. It seeks to invest in all segments of healthcare including discovery and development of novel therapeutics; medical devices and diagnostics; med-tech; life sciences that include biopharmaceuticals and biotechnology platforms; healthcare services; and healthcare information technology. The firm prefers to invest in companies based in the United States and Western Europe. The firm seeks to invest in the biotechnology sector in Canada. The firm typically invests between $10 million and $20 million into each startup before it’s sold or goes public. It will not invest in a company ...

One Sansome Street

Suite 3630

San Francisco, CA 94104

United States

Founded in 1999





Key Executives for Versant Venture Management, LLC

Managing Director
Managing Director
Age: 62
Co-founder & MD
Age: 64
Co-Founder & MD
Age: 71
Managing Director
Age: 77
Compensation as of Fiscal Year 2017.

Versant Venture Management, LLC Key Developments

Versant Ventures, Inc. Presents at The Medtech Conference, Jun-01-2017

Versant Ventures, Inc. Presents at The Medtech Conference, Jun-01-2017. Venue: The Loews Minneapolis Hotel, 601 1st Ave N, Minneapolis, MN 55403, United States. Presentation Date & Speakers: Jun-01-2017, Kevin Hykes, Operating Partner.

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics

Bayer AG and Versant Ventures announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an platform. BlueRock Therapeutics will be led by a team and has assembled its platform through a series of strategic partnerships with academia and industry. To enable BlueRock Therapeutics' platform and pipeline, Bayer and Versant are committing USD 225 million, representing one of the ever series A financings for a biotech company. The funds are projected to give BlueRock Therapeutics at least four years of runway and will allow the new company to advance a number of programs into the clinic, with an initial focus on cardiovascular diseases and neurodegenerative disorders. BlueRock Therapeutics' platform is enabled by strategic partnerships with a number of leading academic and industry collaborators in the U.S., Canada and Japan.

Versant Ventures, Inc. Presents at NY/NJ CEO Conference, Nov-03-2016 11:45 AM

Versant Ventures, Inc. Presents at NY/NJ CEO Conference, Nov-03-2016 11:45 AM. Venue: Apella at Alexandria Center, 450 E. 29 Street, New York, NY 10016, United States. Speakers: Carlo Rizzuto, Partner.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States
123Jump.com, Inc. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

Private Placement
June 22, 2017
Repare Therapeutics Inc.
Private Placement
May 17, 2017
Monteris Medical, Inc.
Private Placement
February 13, 2017
Jecure Therapeutics, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Versant Venture Management, LLC, please visit www.versantventures.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.